Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, Tolerability and Pharmacokinetics of MLN8237 in Japanese Subjects with Advanced Solid Tumors
jRCT2080221283Phase 1
- Sponsor
- Takeda
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in Non-hematologic malignancy, sponsored by Takeda. Primary endpoints: Safety and tolerability of MLN8237 and Pharmacokinetics of MLN8237.
02
Drugs
alisertib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080221283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221283.